Article
Urology & Nephrology
Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, Masha Kocherginsky, Suchitra Swaminathan, Sabah S. Munir, Robert S. Svatek, Timothy Kuzel, Joshua J. Meeks
Summary: Intravesical pembrolizumab combined with BCG is a safe and feasible treatment option for bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer, capable of eliciting strong immune responses.
Article
Oncology
Arjun Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward M. Uchio, Joost L. Boormans, Mathieu Roumiguie, Laurence E. M. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara Frenkl, Ronald de Wit
Summary: This study evaluated the efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The results showed that pembrolizumab monotherapy was well-tolerated and demonstrated promising antitumor activity in this patient population.
Article
Immunology
Chun Jye Lim, Phuong Hoang Diem Nguyen, Martin Wasser, Pavanish Kumar, Yun Hua Lee, Nurul Jannah Mohamed Nasir, Camillus Chua, Liyun Lai, Sharifah Nur Hazirah, Josh Jie Hua Loh, Li Yan Khor, Joe Yeong, Tony Kiat Hon Lim, Alvin Wei Xiang Low, Salvatore Albani, Tsung Wen Chong, Valerie Chew
Summary: This study identified immune subset changes and gene expression features associated with BCG treatment by analyzing patient blood and tissue samples. It also found that baseline densities of non-Treg and CD8(+)PD-1(+) T cells were predictive of response and recurrence-free survival after BCG. Furthermore, the study revealed predictive biomarkers for response and resistance mechanisms to BCG.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Lei Zhang, Yuqing Li, Lingli Zhou, Houhong Zhou, Liefu Ye, Tong Ou, Huaishan Hong, Shiwen Zheng, Ziyu Zhou, Kang Wu, Zeqin Yan, Jean Paul Thiery, Jun Cui, Song Wu
Summary: YTHDF2 is upregulated in bladder cancer and promotes tumor growth by inhibiting RIG-I-mediated immune signaling, highlighting the significance of m(6)A modifications in bladder cancer and providing therapeutic opportunities.
Article
Urology & Nephrology
Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Summary: This study evaluated the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC patients who were ineligible for or declined surgery. The results showed that atezolizumab had a good pathological complete response rate in patients with carcinoma in situ, and some patients had durable responses. However, there were severe treatment-related adverse events in some patients.
Article
Oncology
Kuan-Chun Huang, Dinesh Chanda, Shannon McGrath, Vaishali Dixit, Chi Zhang, Jiayi Wu, Karen Tendyke, Huilan Yao, Renee Hukkanen, Noel Taylor, David Verbel, Dae-Shik Kim, Atsushi Endo, Thomas A. Noland, Yu Chen, Mark Matijevic, John Wang, Janna Hutz, Nadeem Sarwar, Francis G. Fang, Xingfeng Bao
Summary: This study demonstrates that the use of macrocyle-bridged STING agonist E7766 can induce antitumor effects in vitro and in vivo via intravesical instillation in NMIBC tumor models resistant to BCG and anti-PD-1 agents. Activation of the STING pathway in the bladder results in immune cell infiltration and antigen presentation, leading to antitumor activity and immunity. This research provides a rationale for subsequent clinical studies in NMIBC patients.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Immunology
Christopher James, Kayeromi Gomez, Shalin Desai, Hiten D. Patel, Goran Rac, Chirag P. Doshi, Ryan Dornbier, Petar Bajic, Thomas Halverson, Gopal N. Gupta, Marcus L. Quek, Alex Gorbonos, Robert Flanigan, Alan J. Wolfe
Summary: Intravesical therapy (IVT) is the standard treatment for high grade non-muscle invasive bladder cancer (NMIBC), but recurrence is still common. This study aimed to characterize changes in the bladder microbiome during IVT and investigate their correlation with outcomes in patients with NMIBC.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Review
Urology & Nephrology
Lee A. Hugar, Scott M. Gilbert, Wade J. Sexton, Ashish M. Kamat, Roger Li
Summary: This review discusses various immunotherapy methods for treating BCG unresponsive NMIBC and emphasizes the development of novel intravesical treatments. These methods include gene therapy, oncolytic viruses, immunotoxins, as well as the recently approved immune checkpoint inhibitor pembrolizumab for BCG unresponsive NMIBC.
CURRENT OPINION IN UROLOGY
(2021)
Article
Veterinary Sciences
Saraswathi Subramanian, Sreenidhi Srinivasan, Kathiravan Ramaiyan Selvaraju, Priyadharshini Michael Vinoli, Suganya Selladurai, Boominathan Ramasamy, Karthik Kumaragurubaran, Douwe Bakker, Martin Vordermeier, Vivek Kapur, Dhinakar Raj Gopal
Summary: The BCG vaccine provides partial protection against bovine tuberculosis in cattle. A peptide-based defined antigen skin test (DST) has been developed to differentiate between BCG-vaccinated and bTB-infected animals. This study demonstrates that DST retains its diagnostic specificity even after revaccination with BCG.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Review
Oncology
Samantha R. Unsworth-White, Mark O. Kitchen, Richard T. Bryan
Summary: This review examines the evolution of intravesical BCG therapy in IR- and HR-NMIBC. It also discusses new and emerging immunotherapeutics in the management of NMIBC, which may become increasingly important if the global shortage of BCG continues.
Review
Microbiology
Esma Mouhoub, Pilar Domenech, Momar Ndao, Michael B. Reed
Summary: Live attenuated Bacillus Calmette-Guerin (BCG) vaccine is widely used for preventing tuberculosis, but has also shown protection against other pathogens. Recombinant BCG technology has been used to create vaccines that elicit immunity against bacterial, viral, and parasitic diseases. This review aims to provide an overview of rBCG-based vaccines targeting infectious diseases other than TB.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Maria A. Duarte C., Jeismar M. Carballo O., Yetsenia M. De Gouveia, Angie Garcia, Diana Ruiz, Teresa Gledhill, Eglys Gonzalez-Marcano, Ana F. Convit
Summary: ConvitVax is a personalized vaccine for breast cancer treatment, which has been shown to be safe and effective in preclinical studies on BALB/c mice.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
David A. Ostrowski, Raju R. Chelluri, Matthew Herzig, Leilei Xia, Brian D. Cortese, Daniel S. Roberson, Thomas J. Guzzo, Daniel H. J. Lee, S. Bruce Malkowicz
Summary: The study compared the efficacy of reduced-dose induction BCG to full-dose induction BCG in terms of bladder tumor recurrence rate. It was found that reduced-dose induction BCG was associated with a significantly higher risk of recurrence within one year. This suggests that reduced-dose induction BCG may not be equivalent or non-inferior to full-dose administration in the short term.
Article
Biotechnology & Applied Microbiology
Jiang Pi, Zhiyi Zhang, Enzhuo Yang, Lingming Chen, Lingchan Zeng, Yiwei Chen, Richard Wang, Dan Huang, Shuhao Fan, Wensen Lin, Hongbo Shen, Jun-Fa Xu, Gucheng Zeng, Ling Shen
Summary: Engineering Mycobacterium tuberculosis into nanoscale particles improves the safety and efficacy of the TB vaccine, providing better protection against TB infection.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Plant Sciences
Laura Priscila Toledo Bernal, Maicon Matos Leitao, Joyce Alencar Santos Radai, Claudia Andrea Lima Cardoso, Joyce dos Santos Lencina, Thiago Leite Fraga, Arielle Cristina Arena, Saulo Euclides Silva-Filho, Candida Aparecida Leite Kassuya
Summary: This study investigated the analgesic and anti-inflammatory properties of the ethanolic extract from Serjania erecta leaves (EESE) in mice. The results showed that EESE reduced pain response, inhibited leukocyte migration, and decreased neutrophil chemotaxis. Furthermore, EESE exhibited no cytotoxicity in vitro. These findings support the traditional use of S. erecta as a natural analgesic agent.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)